Diana Ernst, RPh

The FDA has approved Vyvgart Hytrulo for generalized myasthenia gravis in adult patients who are AChR antibody positive.

Liqrev® (sildenafil) Oral Suspension has been made available by CMP Pharma for patients who have difficulty swallowing sildenafil tablets.

Novis PR LLC has issued a recall of 1 lot of G-Supress DX Pediatric Drops Cough Suppressant Nasal Decongestant Cherry Flavor.

To reduce the risk for transfusion-transmitted HIV, the FDA has finalized individual risk-based questions to assess blood donor eligibility.

Sepiapterin significantly reduced blood phenylalanine levels in adult and pediatric patients with phenylketonuria.

Positive results were announced from a phase 3 trial evaluating a next-generation, low-dose copper IUD for the prevention of pregnancy.

FDA joint panel vote unanimously to allow for Rx to OTC switch of progestin-only contraceptive pill Opill.

The FDA has approved Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer disease.

The FDA has approved Elfabrio® (pegunigalsidase alfa-iwxj) for the treatment of adults with confirmed Fabry disease.

The FDA has granted final approval to Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

The FDA granted Fast Track designation to AOC 1044 for treating Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping.

Atogepant is an oral calcitonin gene-related peptide receptor antagonist.

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.

To better understand the new phenomenon of “patient influencers”, the authors conducted interviews with individuals who routinely offer advice on health topics on social media.

The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study.

Aponvie is an injectable emulsion formulation of aprepitant.

The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials.

Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.

Donanemab is an antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.

Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.

Leqembi is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.

Researchers used data from the State Unintentional Drug Overdose Reporting System in order to assess trends in gabapentin-involved overdose deaths.

AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.

Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

The independent study conducted by Dan Barouch, MD, PhD, et al of Beth Israel Deaconess Medical Center included a subset of participants from the COV2008 study.

The CDC is recommending that health care providers take a travel history for all suspected and confirmed cases of COVID-19.